Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study

Keyphrases

• Europe 100%
• Cardiometabolic Risk 100%
• Rimonabant 100%
• Weight Loss 50%
• Placebo 16%
• Treatment Group 16%
• Clinically Significant 16%
• AIMS™ 16%
• Receptor Blockers 16%
• Once-daily 16%
• Caloric Restriction 16%
• Body Mass Index 16%
• Tolerability 16%
• Cannabinoid Receptor 1 (CB1R) 16%
• Intention-to-treat 16%
• Dyslipidemia 16%
• Untreated Hypertension 16%

Medicine and Dentistry

• Cardiometabolic Risk 100%
• Rimonabant 100%
• Body Mass Index 16%
• Placebo 16%
• Diet Restriction 16%
• Dyslipidemia 16%
• Receptor Blocking Agent 16%
• Group Therapy 16%
• Intention-to-Treat Analysis 16%
• Cannabinoid 16%

Agricultural and Biological Sciences

• Risk Factor 100%
• Rimonabant 100%
• Body Mass Index 16%
• Placebo 16%
• Dyslipidemia 16%
• Cannabinoid Receptor Type 1 16%